Journal Article Summary
The article investigates the long-term effectiveness and safety of zolpidem extended-release, specifically at a dosage of 12.5 mg, for treating chronic primary insomnia. Chronic insomnia can significantly impact a person's quality of life, leading to difficulties in daily functioning and overall well-being. Understanding how effective zolpidem is over an extended period can help patients and healthcare providers make informed decisions about managing insomnia.
In this study, 1,018 adults aged 18 to 64 with chronic primary insomnia participated in a randomized, double-blind, placebo-controlled trial across multiple centers. Participants were given either zolpidem extended-release or a placebo for 24 weeks, with assessments conducted every four weeks. The results showed that a significant majority of those taking zolpidem reported improvements in sleep quality and next-day functioning compared to those on placebo. Specifically, by week 12, nearly 90% of zolpidem users felt it helped them sleep, and this percentage increased to over 92% by week 24. Improvements were also noted in various sleep-related measures, including sleep onset and total sleep time.
Despite the positive findings, the study has limitations, such as the potential for side effects like headache, anxiety, and drowsiness, which were the most common among zolpidem users. Additionally, while no rebound insomnia was observed after stopping the medication for the first three nights, long-term safety and effects beyond the study duration remain uncertain. Patients considering zolpidem should discuss these findings and any concerns about side effects or long-term use with their healthcare provider to ensure it aligns with their individual health needs.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Krystal Andrew D., Erman Milton, Zammit Gary K., Soubrane C., Roth Thomas. Long-Term Efficacy and Safety of Zolpidem Extended-Release 12.5 mg, Administered 3 to 7 Nights Per Week for 24 Weeks, in Patients With Chronic Primary Insomnia: A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study. Sleep 2008. DOI: 10.1093/sleep/31.1.79. PMID: 18220081. PMCID: PMC2225552.
Featured Pill Pals Product
My Way (Levonorgestrel) 1.5 mg Tablet - Generic For Plan B and Morning After Pill --- Lupin Pharma --- Over The Counter
My Way (Levonorgestrel) 1.5 mg Tablet – Generic For Plan B and Morning After Pill — Lupin Pharma — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
